Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases

Pharmacological Reports

Volumn 66, Issue 5, 2014, Pages 766-775

  Sobczak, Marta ^a   Fabisiak, Adam ^a   Murawska, Natalia ^a   Wesołowska, Ewelina ^a   Wierzbicka, Paulina ^a   Wlazłowski, Marcin ^a   Wójcikowska, Marta ^a   Zatorski, Hubert ^a   Zwolińska, Marta ^a   Fichna, Jakub ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Crohn's disease; Inflammatory bowel diseases; Risk factors; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; ANTIINFLAMMATORY AGENT;

CROHN DISEASE; DIETARY INTAKE; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HUMAN; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASE; MOLECULAR PATHOLOGY; MOOD DISORDER; NONHUMAN; REVIEW; RISK FACTOR; SLEEP DISORDER; SMOKING; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; ULCERATIVE COLITIS; ABDOMINAL PAIN; ANIMAL; DIARRHEA; DRUG DESIGN; GENETIC PREDISPOSITION; INFLAMMATORY BOWEL DISEASES; PATHOPHYSIOLOGY;

ABDOMINAL PAIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIARRHEA; DISEASE PROGRESSION; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 84903118680     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.04.005     Document Type: Review

References (118)

1. A. Schirbel, and C. Fiocchi Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy J Dig Dis 11 5 2010 266 276
2. E.F. Yen, and D.S. Pardi Non-IBD colitides (eosinophilic, microscopic) Best Pract Res Clin Gastroenterol 26 5 2012 611 622
3. N.A. Molodecky, I.S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, and G. Chernoff et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 1 2012 46 54
4. S. Odes, H. Vardi, M. Friger, D. Esser, F. Wolters, and B. Moum et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis Aliment Pharmacol Ther 31 7 2010 735 744
5. W.R. Best, J.M. Becktel, and J.W. Singleton Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI) Gastroenterology 77 4 Pt 2 1979 843 846 (Pubitemid 9257852)
6. R.F. Harvey, and M.J. Bradshaw Measuring Crohn's disease activity Lancet 1 8178 1980 1134 1135
7. J.S. Hyams, G.D. Ferry, F.S. Mandel, J.D. Gryboski, P.M. Kibort, and B.S. Kirschner et al. Development and validation of a pediatric Crohn's disease activity index J Pediatr Gastroenterol Nutr 12 4 1991 439 447
8. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 26 1987 1625 1629 (Pubitemid 18010466)
9. E. Langholz Current trends in inflammatory bowel disease: the natural history Ther Adv Gastroenterol 3 2 2010 77 86
10. H.M. Malaty, J.K. Hou, and S. Thirumurthi Epidemiology of inflammatory bowel disease among an indigent multi-ethnic population in the United States Clin Exp Gastroenterol 3 2010 165 170
11. S. Shivananda, J. Lennard-Jones, R. Logan, N. Fear, A. Price, and L. Carpenter et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD) Gut 39 5 1996 690 697 (Pubitemid 26426470)
12. F. Rieder, E.M. Zimmermann, F.H. Remzi, and W.J. Sandborn Crohn's disease complicated by strictures: a systematic review Gut 62 7 2013 1072 1084
13. L. Lakatos, T. Pandur, G. David, Z. Balogh, P. Kuronya, and A. Tollas et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study World J Gastroenterol 9 10 2003 2300 2307 (Pubitemid 37321464)
14. J.K. Hou, H. El-Serag, and S. Thirumurthi Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review Am J Gastroenterol 104 8 2009 2100 2109
15. I.S. Soon, N.A. Molodecky, D.M. Rabi, W.A. Ghali, H.W. Barkema, and G.G. Kaplan The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis BMC Gastroenterol 12 2012 51
16. J. Halfvarson Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis 17 1 2011 6 12
17. M.E. Spehlmann, A.Z. Begun, J. Burghardt, P. Lepage, A. Raedler, and S. Schreiber Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study Inflamm Bowel Dis 14 7 2008 968 976
18. P.J. Turnbaugh, C. Quince, J.J. Faith, A.C. McHardy, T. Yatsunenko, and F. Niazi et al. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins Proc Natl Acad Sci U S A 107 16 2010 7503 7508
19. A.S. El, B.P. van, M. Derrien, D.J. Lindenbergh-Kortleve, G. Hooiveld, and F. Levenez et al. Temporal and spatial interplay of microbiota and intestinal mucosa drive establishment of immune homeostasis in conventionalized mice Mucosal Immunol 5 5 2012 567 579
20. D.N. Frank, C.E. Robertson, C.M. Hamm, Z. Kpadeh, T. Zhang, and H. Chen et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases Inflamm Bowel Dis 17 1 2011 179 184
21. R. Cooney, J. Baker, O. Brain, B. Danis, T. Pichulik, and P. Allan et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation Nat Med 16 1 2010 90 97
22. Y. Ogura, D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, and R. Ramos et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Nature 411 6837 2001 603 606 (Pubitemid 32531409)
23. J. Cavanaugh NOD2: ethnic and geographic differences World J Gastroenterol 12 23 2006 3673 3677 (Pubitemid 43950944)
24. Z. Nagy, O. Karadi, G. Rumi, G. Rumi Jr., A. Par, and G. Mozsik et al. Crohn's disease is associated with polymorphism of CARD15/NOD2 gene in a Hungarian population Ann N Y Acad Sci 1051 2005 45 51 (Pubitemid 41362731)
25. T. Helio, L. Halme, M. Lappalainen, H. Fodstad, P. Paavola-Sakki, and U. Turunen et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease Gut 52 4 2003 558 562 (Pubitemid 36363411)
26. L.H. Travassos, L.A. Carneiro, M. Ramjeet, S. Hussey, Y.G. Kim, and J.G. Magalhaes et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry Nat Immunol 11 1 2010 55 62
27. K. Cadwell Crohn's disease susceptibility gene interactions, a NOD to the newcomer ATG16L1 Gastroenterology 139 5 2010 1448 1450
28. A.M. Muise, T.D. Walters, W.K. Glowacka, A.M. Griffiths, B.Y. Ngan, and H. Lan et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease Gut 58 8 2009 1121 1127
29. R.D. Eri, R.J. Adams, T.V. Tran, H. Tong, I. Das, and D.K. Roche et al. An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity Mucosal Immunol 4 3 2011 354 364
30. S.A. McCarroll, A. Huett, P. Kuballa, S.D. Chilewski, A. Landry, and P. Goyette et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease Nat Genet 40 9 2008 1107 1112
31. S.W. Beaven, and M.T. Abreu Biomarkers in inflammatory bowel disease Curr Opin Gastroenterol 20 4 2004 318 327 (Pubitemid 38813672)
32. C.M. Panwala, J.C. Jones, and J.L. Viney A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis J Immunol 161 10 1998 5733 5744 (Pubitemid 28519142)
33. M. Fasseu, X. Treton, C. Guichard, E. Pedruzzi, D. Cazals-Hatem, and C. Richard et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease PLoS ONE 5 10 2010
34. P.J. Koelink, S.A. Overbeek, S. Braber, K.P. de, G. Folkerts, and M.J. Smit et al. Targeting chemokine receptors in chronic inflammatory diseases: an extensive review Pharmacol Ther 133 1 2012 1 18
35. G. Monteleone, F. Trapasso, T. Parrello, L. Biancone, A. Stella, and R. Iuliano et al. Bioactive IL-18 expression is up-regulated in Crohn's disease J Immunol 163 1 1999 143 147 (Pubitemid 29295835)
36. G. Monteleone, L. Biancone, R. Marasco, G. Morrone, O. Marasco, and F. Luzza et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells Gastroenterology 112 4 1997 1169 1178 (Pubitemid 27157528)
37. F. Heller, P. Florian, C. Bojarski, J. Richter, M. Christ, and B. Hillenbrand et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution Gastroenterology 129 2 2005 550 564 (Pubitemid 41096643)
38. S.A. Di, P. Biancheri, L. Rovedatti, T.T. MacDonald, and G.R. Corazza New pathogenic paradigms in inflammatory bowel disease Inflamm Bowel Dis 18 2 2012 368 371
39. J.K. Triantafillidis, E. Merikas, and A. Gikas Psychological factors and stress in inflammatory bowel disease Expert Rev Gastroenterol Hepatol 7 3 2013 225 238
40. C.K. Zhang, J. Hewett, J. Hemming, T. Grant, H. Zhao, and C. Abraham et al. The influence of depression on quality of life in patients with inflammatory bowel disease Inflamm Bowel Dis 19 8 2013 1732 1739
41. K. Kemp, J. Griffiths, and K. Lovell Understanding the health and social care needs of people living with IBD: a meta-synthesis of the evidence World J Gastroenterol 18 43 2012 6240 6249
42. A. Sonnenberg, and T.R. Koch Period and generation effects on mortality from idiopathic inflammatory bowel disease Dig Dis Sci 34 11 1989 1720 1729 (Pubitemid 19275333)
43. C.P. Selinger, S. Lal, J. Eaden, D.B. Jones, P. Katelaris, and G. Chapman et al. Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease J Crohns Colitis 7 6 2013 e214 e218
44. G. Hauser, M. Tkalcic, D. Stimac, S. Milic, and B.M. Sincic Gender related differences in quality of life and affective status in patients with inflammatory bowel disease Coll Antropol 35 Suppl. 2 2011 203 207
45. J.E. Mawdsley, M.G. Macey, R.M. Feakins, L. Langmead, and D.S. Rampton The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis Gastroenterology 131 2 2006 410 419 (Pubitemid 44142453)
46. J.D. Soderholm, and M.H. Perdue Stress and gastrointestinal tract. II. Stress and intestinal barrier function Am J Physiol Gastrointest Liver Physiol 280 1 2001 G7 G13
47. P. Jantchou, S. Morois, F. Clavel-Chapelon, M.C. Boutron-Ruault, and F. Carbonnel Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study Am J Gastroenterol 105 10 2010 2195 2201
48. N. Sakamoto, S. Kono, K. Wakai, Y. Fukuda, M. Satomi, and T. Shimoyama et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan Inflamm Bowel Dis 11 2 2005 154 163 (Pubitemid 40711220)
49. R. Shoda, K. Matsueda, S. Yamato, and N. Umeda Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan Am J Clin Nutr 63 5 1996 741 745 (Pubitemid 26126594)
50. M.G. Russel, L.G. Engels, J.W. Muris, C.B. Limonard, A. Volovics, and R.J. Brummer et al. Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors Eur J Gastroenterol Hepatol 10 3 1998 243 249 (Pubitemid 28175002)
51. H. Boeing, A. Bechthold, A. Bub, S. Ellinger, D. Haller, and A. Kroke et al. Critical review: vegetables and fruit in the prevention of chronic diseases Eur J Nutr 51 6 2012 637 663
52. H. Asakura, K. Suzuki, T. Kitahora, and T. Morizane Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J Gastroenterol Hepatol 23 12 2008 1794 1801
53. B. Kalyanaraman Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms Redox Biol 1 1 2013 244 257
54. Y. Kuno, K. Ina, T. Nishiwaki, T. Tsuzuki, M. Shimada, and A. Imada et al. Possible involvement of neutrophil elastase in impaired mucosal repair in patients with ulcerative colitis J Gastroenterol 37 Suppl. 14 2002 22 32 (Pubitemid 35385922)
55. B. Beltran, P. Nos, F. Dasi, M. Iborra, G. Bastida, and M. Martinez et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease Inflamm Bowel Dis 16 1 2010 76 86
56. P.L. Beck, R. Xavier, J. Wong, I. Ezedi, H. Mashimo, and A. Mizoguchi et al. Paradoxical roles of different nitric oxide synthase isoforms in colonic injury Am J Physiol Gastrointest Liver Physiol 286 1 2004 G137 G147
57. J.R. Kanwar, R.K. Kanwar, H. Burrow, and S. Baratchi Recent advances on the roles of NO in cancer and chronic inflammatory disorders Curr Med Chem 16 19 2009 2373 2394
58. K. Palatka, Z. Serfozo, Z. Vereb, Z. Hargitay, B. Lontay, and F. Erdodi et al. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease Scand J Gastroenterol 40 6 2005 670 680 (Pubitemid 40827529)
59. S. Blau, R. Kohen, P. Bass, and A. Rubinstein Relation between colonic inflammation severity and total low-molecular-weight antioxidant profiles in experimental colitis Dig Dis Sci 45 6 2000 1180 1187 (Pubitemid 30409464)
60. L.M. Higuchi, H. Khalili, A.T. Chan, J.M. Richter, A. Bousvaros, and C.S. Fuchs A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women Am J Gastroenterol 107 9 2012 1399 1406
61. J. McGrath, J.W. McDonald, and J.K. Macdonald Transdermal nicotine for induction of remission in ulcerative colitis Cochrane Database Syst Rev 4 2004 CD004722
62. R. Eliakim, and F. Karmeli Divergent effects of nicotine administration on cytokine levels in rat small bowel mucosa, colonic mucosa, and blood Isr Med Assoc J 5 3 2003 178 180 (Pubitemid 36469332)
63. T. Ali, M.F. Madhoun, W.C. Orr, and D.T. Rubin Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients Inflamm Bowel Dis 19 11 2013 2440 2443
64. Z. Li, Zhang dK, W.Q. Yi, Q. Ouyang, Y.Q. Chen, and H.T. Gan NF-kappaB p65 antisense oligonucleotides may serve as a novel molecular approach for the treatment of patients with ulcerative colitis Arch Med Res 39 8 2008 729 734
65. S. Danese, J.F. Colombel, L. Peyrin-Biroulet, P. Rutgeerts, and W. Reinisch Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future Aliment Pharmacol Ther 37 9 2013 855 866
66. C.G. af Bjorkesten, U. Nieminen, T. Sipponen, U. Turunen, P. Arkkila, and M. Farkkila Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease Scand J Gastroenterol 48 5 2013 543 551
67. T. Olsen, G. Cui, R. Goll, A. Husebekk, and J. Florholmen Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis Scand J Gastroenterol 44 6 2009 727 735
68. M.L. Melo, G.A. Brito, R.C. Soares, S.B. Carvalho, J.V. Silva, and P.M. Soares et al. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide Cancer Chemother Pharmacol 61 5 2008 775 784 (Pubitemid 351302033)
69. J. Bollrath, T.J. Phesse, V. von B, T. Putoczki, M. Bennecke, and T. Bateman et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis Cancer Cell 15 2 2009 91 102
70. C.T. Weaver, L.E. Harrington, P.R. Mangan, M. Gavrieli, and K.M. Murphy Th17: an effector CD4T cell lineage with regulatory T cell ties Immunity 24 6 2006 677 688 (Pubitemid 43867371)
71. G. Monteleone, I. Monteleone, D. Fina, P. Vavassori, B.G. Del Vecchio, and R. Caruso et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease Gastroenterology 128 3 2005 687 694 (Pubitemid 40585371)
72. A. Lopez, and L. Peyrin-Biroulet 5-Aminosalicylic acid and chemoprevention: does it work? Dig Dis 31 2 2013 248 253
73. S.M. McKenzie, W.F. Doe, and G.D. Buffinton 5-Aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells Gut 44 2 1999 180 185 (Pubitemid 29119360)
74. J.K. Marshall, and E.J. Irvine Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis Am J Gastroenterol 95 7 2000 1628 1636 (Pubitemid 30484995)
75. J.K. Marshall, M. Thabane, A.H. Steinhart, J.R. Newman, A. Anand, and E.J. Irvine Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 1 2010 CD004115
76. C. Girlich, and J. Scholmerich Topical delivery of steroids in inflammatory bowel disease Curr Drug Deliv 9 4 2012 345 349
77. T. Nunes, A.M. Barreiro-de, I. Marin-Jimenez, P. Nos, and M. Sans Oral locally active steroids in inflammatory bowel disease J Crohns Colitis 7 3 2013 183 191
78. G. Jonsson, A. Astrom, and P. Andersson Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver Drug Metab Dispos 23 1 1995 137 142
79. R. Hamedani, R.D. Feldman, and B.G. Feagan Review article: drug development in inflammatory bowel disease: budesonide - a model of targeted therapy Aliment Pharmacol Ther 11 Suppl. 3 1997 98 107
80. Y. Murata, Y. Ishiguro, J. Itoh, A. Munakata, and Y. Yoshida The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis J Gastroenterol 30 Suppl. 8 1995 56 60
81. U.R. Juergens, F. Jager, W. Darlath, M. Stober, H. Vetter, and A. Gillissen Comparison of in vitro-activity of commonly used topical glucocorticoids on cytokine- and phospholipase inhibition Eur J Med Res 9 8 2004 383 390
82. C. Papi, A. Aratari, A. Moretti, M. Mangone, G. Margagnoni, and M. Koch et al. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates Dig Dis Sci 55 7 2010 2002 2007
83. T. Nunes, A.M. Barreiro-de, P. Nos, I. Marin-Jimenez, F. Bermejo, and D. Ceballos et al. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU study J Crohns Colitis 4 6 2010 629 636
84. J.S. Maltzman, and G.A. Koretzky Azathioprine: old drug, new actions J Clin Invest 111 8 2003 1122 1124 (Pubitemid 36519929)
85. C.W. Thomas, G.M. Myhre, R. Tschumper, R. Sreekumar, D. Jelinek, and D.J. McKean et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines J Pharmacol Exp Ther 312 2 2005 537 545 (Pubitemid 40189550)
86. R. Yamaguchi, M. Hosaka, S. Torii, N. Hou, N. Saito, and Y. Yoshimoto et al. Cyclophilin C-associated protein regulation of phagocytic functions via NFAT activation in macrophages Brain Res 1397 2011 55 65
87. S. Renna, A. Orlando, and M. Cottone Randomized controlled trials in perianal Crohn's disease Rev Recent Clin Trials 7 4 2012 297 302
88. A.C. Ford, R.J. Towler, P. Moayyedi, D.M. Chalmers, and A.T. Axon Mycophenolate mofetil in refractory inflammatory bowel disease Aliment Pharmacol Ther 17 11 2003 1365 1369 (Pubitemid 36774143)
89. S. Palaniappan, A.C. Ford, D. Greer, S.M. Everett, D.M. Chalmers, and A.T. Axon et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease Inflamm Bowel Dis 13 12 2007 1488 1492
90. S.L. Wang, Z.R. Wang, and C.Q. Yang Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease Exp Ther Med 4 6 2012 1051 1056
91. V. Patel, J.K. Macdonald, J.W. McDonald, and N. Chande Methotrexate for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 4 2009 CD006884
92. S. Willot, A. Noble, and C. Deslandres Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center Inflamm Bowel Dis 17 12 2011 2521 2526
93. B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, and J. Ghrayeb Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 3 1995 251 259
94. A. Cassinotti, and S. Travis Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review Inflamm Bowel Dis 15 8 2009 1264 1275
95. L. Peyrin-Biroulet, P. Deltenre, S.N. de, J. Branche, W.J. Sandborn, and J.F. Colombel Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 6 2008 644 653 (Pubitemid 351783447)
96. J.P. Ahluwalia Immunotherapy in inflammatory bowel disease Med Clin North Am 96 3 2012 525 544 x
97. S.K. Mohapatra, A.J. Guri, M. Climent, C. Vives, A. Carbo, and W.T. Horne et al. Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease PLoS ONE 5 4 2010 e10215
98. V. Pasceri, J.S. Cheng, J.T. Willerson, and E.T. Yeh Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 21 2001 2531 2534 (Pubitemid 32521959)
99. J.D. Ramakers, M.I. Verstege, G. Thuijls, A.A. Te Velde, R.P. Mensink, and J. Plat The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis J Clin Immunol 27 3 2007 275 283 (Pubitemid 46790815)
100. R. Hontecillas, W.T. Horne, M. Climent, A.J. Guri, C. Evans, and Y. Zhang et al. Immunoregulatory mechanisms of macrophage PPAR-gamma in mice with experimental inflammatory bowel disease Mucosal Immunol 4 3 2011 304 313
101. J.D. Lewis, G.R. Lichtenstein, J.J. Deren, B.E. Sands, S.B. Hanauer, and J.A. Katz et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial Gastroenterology 134 3 2008 688 695 (Pubitemid 351312727)
102. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, and S. Katz et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 4 2008 1130 1141
103. S. Keshav, T. Vanasek, Y. Niv, R. Petryka, S. Howaldt, and M. Bafutto et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease PLoS ONE 8 3 2013 e60094
104. S.R. Targan, B.G. Feagan, R.N. Fedorak, B.A. Lashner, R. Panaccione, and D.H. Present et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterol 132 5 2007 1672 1683 (Pubitemid 46695722)
105. M. Sobczak, M. Salaga, M.A. Storr, and J. Fichna Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives J Gastroenterol 49 1 2014 24 45
106. D. Philippe, L. Dubuquoy, H. Groux, V. Brun, M.T. Chuoi-Mariot, and C. Gaveriaux-Ruff et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation Clin Invest 111 9 2003 1329 1338 (Pubitemid 36554703)
107. M. Sobczak, P.K. Zakrzewski, A.I. Cygankiewicz, A. Mokrowiecka, C. Chen, and M. Sałaga et al. Anti-inflammatory action of a novel orally-available peptide 317 in mouse models of inflammatory bowel diseases Pharmacol Rep 2014 10.1016/j.pharep.2014.03.007 [in press]
108. M. Sobczak, M. Salaga, M. Storr, and J. Fichna Nociceptin/orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases Curr Drug Targets 14 10 2013 1203 1209
109. M. Sobczak, A. Mokrowiecka, A.I. Cygankiewicz, P.K. Zakrzewski, M. Salaga, and M. Storr et al. Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases J Pharmacol Exp Ther 348 3 2014 401 409
110. M. Salaga, M. Sobczak, and J. Fichna Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract Eur J Pharm Sci 52 2014 173 179
111. M. Salaga, A. Mokrowiecka, P.K. Zakrzewski, A. Cygankiewicz, E. Leishman, and M. Sobczak et al. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH) J Crohns Colitis 2014 10.1016/j.crohns.2014. 01.025
112. S. Cuzzocrea, E. Mazzon, I. Serraino, V. Lepore, M.L. Terranova, and A. Ciccolo et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis J Pineal Res 30 1 2001 1 12 (Pubitemid 32056605)
113. E. Mazzon, E. Esposito, C. Crisafulli, L. Riccardi, C. Muia, and B.P. Di et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis J Pineal Res 41 4 2006 363 373 (Pubitemid 44498223)
114. I.A. Lee, D. Low, A. Kamba, V. Llado, and E. Mizoguchi Oral caffeine administration ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial cells J Gastroenterol 2013 10.1007/s00535-013-0865-3 [in press]
115. I.A. Lee, A. Kamba, D. Low, and E. Mizoguchi Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease World J Gastroenterol 20 5 2014 1127 1138
116. M.D. Bhavsar, and M.M. Amiji Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease Gene Ther 15 17 2008 1200 1209
117. C. Kriegel, and M.M. Amiji Dual TNF-alpha/cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease Clin Transl Gastroenterol 2 2011 e2
118. C. Kriegel, H. Attarwala, and M. Amiji Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract Adv Drug Deliv Rev 65 6 2013 891 901